Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, Díaz-Mediavilla J, Bustelos R, Fernández-Aceñero MJ, Cabrera JR; Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA. Peñalver FJ, et al. Ann Hematol. 2010 Nov;89(11):1073-80. doi: 10.1007/s00277-010-0997-y. Epub 2010 Jun 5. Ann Hematol. 2010. PMID: 20526716
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM. Barbui T, et al. Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. Blood Cancer J. 2022. PMID: 36385103 Free PMC article. No abstract available.
Breakthrough infections in MPN-COVID vaccinated patients.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Barbui T, et al. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. Blood Cancer J. 2022. PMID: 36379921 Free PMC article. No abstract available.
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Díaz-González Á, Mora E, Avetisyan G, Furió S, De la Puerta R, Gil JV, Liquori A, Villamón E, García-Hernández C, Santiago M, García-Ruiz C, Llop M, Ferrer-Lores B, Barragán E, García-Palomares S, Mayordomo E, Luna I, Vicente A, Cordón L, Senent L, Álvarez-Larrán A, Cervera J, De la Rubia J, Hernández-Boluda JC, Such E. Díaz-González Á, et al. Cancers (Basel). 2023 Jun 2;15(11):3039. doi: 10.3390/cancers15113039. Cancers (Basel). 2023. PMID: 37297002 Free PMC article.
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, Martínez-Ávila JC, Hernández-Boluda JC, Ferrer-Marín F, Radia DH, Mora E, Francis S, González-Martínez T, Goddard K, Pérez-Encinas M, Narayanan S, Raya JM, Singh V, Gutiérrez X, Toth P, Amat-Martínez P, Mcilwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufián L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martínez-López J, Ayala R, Cross NCP. Carreño-Tarragona G, et al. Blood Adv. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204. Blood Adv. 2023. PMID: 36375042 Free PMC article.
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M, López-Guerra M, Arellano-Rodrigo E, Rozman M, Carbonell S, Guijarro F, Santaliestra M, Triguero A, Colomer D, Cervantes F, Álvarez-Larrán A. Garrote M, et al. Cancers (Basel). 2023 Jul 31;15(15):3904. doi: 10.3390/cancers15153904. Cancers (Basel). 2023. PMID: 37568719 Free PMC article.
Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR; Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP. Peñalver FJ, et al. Ann Hematol. 2006 Jun;85(6):400-6. doi: 10.1007/s00277-005-0073-1. Epub 2006 Mar 21. Ann Hematol. 2006. PMID: 16550390
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Hernández-Boluda JC, Pereira A, Cervantes F, Gómez M, Arellano-Rodrigo E, Alvarez-Larrán A, Ferrer-Marín F, Kerguelen A, Márquez JA, Antelo ML, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Ann Hematol. 2013 Jun;92(6):771-5. doi: 10.1007/s00277-013-1683-7. Epub 2013 Jan 26. Ann Hematol. 2013. PMID: 23354997
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Alvarez-Larrán A, et al. Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2. Ann Hematol. 2014. PMID: 24981691 Clinical Trial.
163 results